Allison Y Zhong1, Leonardino A Digma1, Troy Hussain1, Christine H Feng1, Christopher C Conlin2, Karen Tye1, Asona J Lui1, Maren MS Andreassen3, Ana E Rodríguez-Soto2, Roshan Karunamuni1, Joshua Kuperman2, Rebecca Rakow-Penner2, Michael E Hahn2, Anders M Dale2,4, and Tyler M Seibert1,2,5
1Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA, United States, 2Department of Radiology, University of California San Diego, La Jolla, CA, United States, 3Department of Circulation and Medical Imaging, Norwegian University of Science and Technology, Trondheim, Norway, 4Department of Neurosciences, University of California San Diego, La Jolla, CA, United States, 5Department of Bioengineering, University of California San Diego, La Jolla, CA, United States
1Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA, United States, 2Department of Radiology, University of California San Diego, La Jolla, CA, United States, 3Department of Circulation and Medical Imaging, Norwegian University of Science and Technology, Trondheim, Norway, 4Department of Neurosciences, University of California San Diego, La Jolla, CA, United States, 5Department of Bioengineering, University of California San Diego, La Jolla, CA, United States
RSI-MRI performed well as a quantitative classifier of higher-grade prostate cancer in a retrospective series, with superior detection compared to conventional ADC and comparable performance to expert PI-RADS interpretation.
Figure 2. Receiving operator characteristic (ROC) curves for conventional ADC (dark gray), RSI-C1 (green), and PI-RADS v2.x (light gray), for the patient-level detection of higher-grade prostate cancer.
Figure 1. Histograms of (A) conventional ADC (lowest voxel value in prostate), (B) RSI-C1 (highest voxel value in prostate), and (C) highest PI-RADS category (v2 prior to 2019, v2.1 in 2019). Blue: Patients with no cancer or low-grade cancer. Orange: Patients with higher-grade (grade group ≥2) prostate cancer. Brown: where blue and orange overlap.
